Title

Bellicum to Participate in Two Upcoming Virtual Investor Conferences

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program

Bellicum to Participate in Two Upcoming Virtual Investor Conferences

Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update  

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Completes Sale of Houston Facility

Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update

Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Announces Reverse Stock Split

Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson

Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium